We are live on ! Find out more
CVS icon

CVS Health

1,654 hedge funds and large institutions have $54.6B invested in CVS Health in 2019 Q2 according to their latest regulatory filings, with 123 funds opening new positions, 754 increasing their positions, 660 reducing their positions, and 154 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more funds holding in top 10

Funds holding in top 10: 3548 (+13)

14% more repeat investments, than reductions

Existing positions increased: 754 | Existing positions reduced: 660

1% less capital invested

Capital invested by funds: $55.1B → $54.6B (-$425M)

1.44% less ownership

Funds ownership: 78.75%77.31% (-1.4%)

3% less funds holding

Funds holding: 1,7081,654 (-54)

20% less first-time investments, than exits

New positions opened: 123 | Existing positions closed: 154

20% less call options, than puts

Call options by funds: $1.14B | Put options by funds: $1.44B

Holders
1,654
Holders Change
-54
Holders Change %
-3.16%
% of All Funds
35.92%
Holding in Top 10
48
Holding in Top 10 Change
+13
Holding in Top 10 Change %
+37.14%
% of All Funds
1.04%
New
123
Increased
754
Reduced
660
Closed
154
Calls
$1.14B
Puts
$1.44B
Net Calls
-$291M
Net Calls Change
+$32.6M
Name Holding Trade Value Shares
Change
Change in
Stake
HR
276
Howe & Rusling
New York
$13.2M +$2.59M +48,039 +25%
QOP
277
Quinn Opportunity Partners
Virginia
$13.2M +$485K +9,000 +4%
HT
278
HAP Trading
New York
$13.1M -$6.72M -124,705 -34%
Calamos Advisors
279
Calamos Advisors
Illinois
$13.1M -$604K -11,223 -4%
Public Employees Retirement Association of Colorado
280
Public Employees Retirement Association of Colorado
Colorado
$12.9M -$190K -3,537 -1%
SDIC
281
South Dakota Investment Council
South Dakota
$12.8M -$1.08M -20,087 -8%
TNB
282
Thomasville National Bank
Georgia
$12.6M +$554K +10,295 +5%
DIA
283
Davidson Investment Advisors
Montana
$12.6M +$5.33M +98,887 +75%
HCM
284
Howland Capital Management
Massachusetts
$12.6M +$495K +9,191 +4%
MOACM
285
Mutual of America Capital Management
New York
$12.5M +$127K +2,365 +1%
EIA
286
Edgemoor Investment Advisors
Maryland
$12.5M +$12.3M +229,168 New
FT
287
Fiduciary Trust
Massachusetts
$12.5M -$1.1M -20,378 -8%
ZIG
288
Zurich Insurance Group
Switzerland
$12.4M +$4.45M +82,545 +57%
EIP
289
Epoch Investment Partners
New York
$12.3M +$3.24M +60,129 +36%
VCM
290
Violich Capital Management
California
$12.2M +$28.3K +526 +0.2%
NPA
291
Nichols & Pratt Advisers
Massachusetts
$12.1M +$399K +7,404 +3%
TS
292
Twin Securities
New York
$12.1M -$16.9M -314,098 -59%
NB
293
Norinchukin Bank
Japan
$12.1M -$4.91M -91,092 -29%
RIL
294
Rothschild Investment LLC
Illinois
$12.1M -$240K -4,448 -2%
RS
295
Robeco Schweiz
Switzerland
$12.1M +$1.8M +33,409 +18%
Nomura Holdings
296
Nomura Holdings
Japan
$12.1M +$6.13M +113,856 +106%
AG
297
Advisor Group
Arizona
$11.9M +$983K +18,253 +9%
Mitsubishi UFJ Asset Management
298
Mitsubishi UFJ Asset Management
Japan
$11.9M +$2.37M +44,003 +25%
VWM
299
Valley Wealth Managers
New Jersey
$11.8M +$986K +18,302 +9%
Skandinaviska Enskilda Banken (SEB)
300
Skandinaviska Enskilda Banken (SEB)
Sweden
$11.8M -$12.3M -228,400 -51%

CVS Hedge Fund Activity: Q2 2019 in Review

1,654 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in CVS Health (CVS) for Q2 2019, worth a combined $54.6B — down 0.77% from $55.1B a quarter earlier.

Sellers outnumbered buyers: 154 funds closed out of CVS and 123 opened new positions — a net loss of 31 holders — while 660 trimmed existing stakes and 754 added.

The largest buyer was Nuveen, adding an estimated $648M. The largest seller was T. Rowe Price Associates, cutting an estimated $321M.

  • 1,654 institutional investors held CVS Health (CVS) as of Q2 2019, down from 1,708 in Q1 2019.
  • Funds reported $54.6B of CVS Health stock for Q2 2019, down 0.77% quarter-over-quarter.
  • 123 funds opened new CVS Health positions in Q2 2019 and 154 closed out, a net change of -31 holders.
  • The largest CVS Health buyer in Q2 2019 was Nuveen, an estimated $648M added.
  • The largest CVS Health seller in Q2 2019 was T. Rowe Price Associates, an estimated $321M sold.

Based on aggregated 13F filings for Q2 2019.